Catalog No.
EHJ24001
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Met1-Asn692
Predicted molecular weight
74.3 kDa
Nature
Recombinant
Concentration
0.74mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q8NBP7
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
Correlation between clinical classification and genetic analysis of familial hypercholesterolemia in premature coronary artery disease in a cohort of Egyptian patients., PMID:40517278
The EGR3 gene modulates CRP and VCAM-1 expression to promote the development of atherosclerosis., PMID:40513687
Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention., PMID:40511612
Circulating protein biomarkers and their association with vulnerable plaque characteristics - a PROSPECT II substudy., PMID:40503438
Fucosterol exerts an anti-atherosclerotic action via NF-κB and p38/Erk MAPK signaling pathways., PMID:40502621
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial., PMID:40480650
PCSK9 inhibition mitigates vulnerable plaque formation induced by hyperhomocysteinemia through regulating lipid metabolism and inflammation., PMID:40480522
Clinically relevant dosing of miR-145 micelles curbs atherosclerosis in vivo., PMID:40480516
A multivariable cis-Mendelian randomization method robust to weak instrument bias and horizontal pleiotropy bias., PMID:40471990
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis., PMID:40467521
PCSK9 is upregulated and correlated with more severe disease condition but fails to predict treatment outcomes in psoriasis patients., PMID:40464661
Genetic Factors Associated With Myocardial Infarction in Saudi Arabia., PMID:40463733
Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE-/- mice., PMID:40462197
Estimated Theoretical Benefit of Aggressive LDL Lowering in Patients With Symptomatic Intracranial Atherosclerosis., PMID:40446174
Assessing the impact of PCSK9 and HMGCR inhibitor on reproductive endocrine diseases: A drug-target Mendelian randomization analysis., PMID:40441203
Cholesteryl Ester Transfer Protein Deficiency and Hyperalphalipoproteinemia., PMID:40436797
PCSK9 is a passenger gene in head and neck cancer with minimal pathological influence., PMID:40435597
Endothelial Nrf2 deficiency promotes atherosclerotic lesion formation by shaping a proinflammatory niche., PMID:40404122
ASGR1 inhibitors, inflammation, and heart failure: A Mendelian randomization analysis., PMID:40391737
Structural dynamics of LDL receptor interactions with E498A and R499G variants of PCSK9., PMID:40388017
An evaluation of recaticimab for the treatment of hypercholesterolemia., PMID:40380894
A pH-Sensitive NIR Fluorescent Probe as a Protagonist in the Discovery of New LC3 Ligands Facilitating the Construction of ATTECs., PMID:40375755
(-)-Oleuropein as a Novel Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence Suppressor via Targeting PCSK9-LDLR Axis., PMID:40362754
Genetic Variants, Bioactive Compounds, and PCSK9 Inhibitors in Hyper-LDL-Cholesterolemia: A GWAS and In Silico Study on Cardiovascular Disease Risk., PMID:40362720
Short-term effects of PCSK-9 inhibitors on percutaneous coronary intervention in patients with acute coronary syndrome., PMID:40360221
Inhibition of PCSK9 with polypurine reverse hoogsteen hairpins: A novel gene therapy approach., PMID:40360039
Investigation of the interplay of PCSK9, cardiac dynamics, oxidative stress in coronary artery disease: case-control study., PMID:40357205
Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies., PMID:40354680
PCSK9 in Vascular Aging and Age-Related Diseases., PMID:40354375
RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: A drug-target Mendelian randomization study., PMID:40347490
Proprotein convertase subtilisin/kexin type 9 contributes to cisplatin-induced acute kidney injury by interacting with cyclase-associated protein 1 to promote megalin lysosomal degradation., PMID:40339661
Impaired CAMK4 Activity Limits Atherosclerosis and Reprograms Myelopoiesis., PMID:40336480
Combining genetic proxies of drug targets and time-to-event analyses from longitudinal observational data to identify target patient populations., PMID:40335923
PCSK9 promotes progression of anaplastic thyroid cancer through E-cadherin endocytosis., PMID:40328788
Kratom leaf extracts exert hypolipidaemic effects via the modulation of PCSK9 and LDLR pathways in HepG2 cells., PMID:40325086
Impairment of endothelial MerTK accelerates atherosclerosis development., PMID:40321244
Impact of PCSK9 inhibitors on bleeding and adverse outcomes in post-PCI patients undergoing antiplatelet therapy: A real-world cohort study., PMID:40320148
Potential of CETP inhibition in treating dyslipidemia in systemic lupus erythematosus: Novel and comprehensive evidence from clinical studies and Mendelian randomization., PMID:40315629
Prescriber Uptake and Use of Novel Lipid-Lowering Therapies., PMID:40314342
Impact of a personalized, strike early and strong approach on non-HDL-cholesterol levels and outcome in patients with acute myocardial infarction., PMID:40311694
Revisiting the role of GDF15 in atherosclerosis in mouse and human., PMID:40307459
Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects., PMID:40305153
Oral PCSK9 Inhibitors: Will They Work?, PMID:40304930
Association between lipid-lowering drug targets and the risk of cystic kidney disease: a drug-target Mendelian randomization analysis., PMID:40289090
A Novel Screening Approach for Familial Hypercholesterolemia: A Genetic Study on Patients Detected Using Preexisting Centralized Analytics., PMID:40283609
Elucidation of Mechanism of Action in Drug Invention: Using Stable Isotope Tracers to Unravel Biochemical Kinetics., PMID:40281645
Gastrodin attenuates hypercholesterolaemia through regulating the PCSK9/LDLR signalling pathway by suppressing HNF-1α and activating FoxO3a., PMID:40279963
Association of APOB (rs515135) and PCSK9 (rs505151) gene polymorphisms with CAD in the Indian population., PMID:40270278
Hepatoprotective and Antiatherosclerotic Effects of Oleoylethanolamide-Based Dietary Supplement in Dietary-Induced Obesity in Mice., PMID:40265441
Recent Advances in the Management of Dyslipidemia: A Systematic Review., PMID:40264627
For research use only. Not for human or drug use.
